Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...

A combination treatment of semaglutide, trevogrumad and garetosmab causes fat loss and muscle growth in primate trials. Full ...

Regeneron Pharmaceuticals said on Monday its experimental weight-loss drug combination helped preserve muscle mass in a ...

By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with ...

Regeneron Pharmaceuticals (REGN) reported interim results from a mid-stage trial testing combinations of semaglutide with experimental antibodies, trevogrumab and garetosmab, for treating obesity.

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies ...

REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently announced a strategic in-licensing agreement with Hansoh Pharmaceuticals, acquiring rights for a dual GLP-1/GIP receptor agonist, HS-20094.